Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
2005 1
2007 2
2008 10
2009 11
2010 7
2011 1
2016 2
2017 1
2018 1
2019 1
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis.
Katchamart W, Bourré-Tessier J, Donka T, Drouin J, Rohekar G, Bykerk VP, Haraoui B, Leclerq S, Mosher DP, Pope JE, Shojania K, Thomson J, Thorne JC, Bombardier C; Canadian 3e Initiative Consensus Group. Katchamart W, et al. J Rheumatol. 2010 Jul;37(7):1422-30. doi: 10.3899/jrheum.090978. Epub 2010 Jun 1. J Rheumatol. 2010. PMID: 20516029 Free article. Review.
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
Ferdowsi N, Huq M, Stevens W, Hudson M, Wang M, Tay T, Burchell JL, Mancuso S, Rabusa C, Sundararajan V, Prior D, Proudman SM, Baron M, Nikpour M; Scleroderma Clinical Trials Consortium Damage Index Working Group, The Australian Scleroderma Interest Group, Canadian Scleroderma Research Group; Scleroderma Clinical Trials Consortium Damage Index Working Group, TheAustralian Scleroderma Interest Group, Canadian Scleroderma Research Group. Ferdowsi N, et al. Ann Rheum Dis. 2019 Jun;78(6):807-816. doi: 10.1136/annrheumdis-2018-214764. Epub 2019 Mar 30. Ann Rheum Dis. 2019. PMID: 30928903
Prediction of damage trajectories in systemic sclerosis using group-based trajectory modelling.
Baron M, Barbacki A, Man A, de Vries-Bouwstra JK, Johnson D, Stevens W, Osman M, Wang M, Zhang Y, Sahhar J, Ngian GS, Proudman S, Nikpour M; Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group. Baron M, et al. Rheumatology (Oxford). 2023 Sep 1;62(9):3059-3066. doi: 10.1093/rheumatology/kead002. Rheumatology (Oxford). 2023. PMID: 36625513 Free PMC article.
Work disability in systemic sclerosis.
Hudson M, Steele R, Lu Y, Thombs BD; Canadian Scleroderma Research Group; Baron M. Hudson M, et al. J Rheumatol. 2009 Nov;36(11):2481-6. doi: 10.3899/jrheum.081237. Epub 2009 Oct 1. J Rheumatol. 2009. PMID: 19797513
Early Mortality in a Multinational Systemic Sclerosis Inception Cohort.
Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, Tatibouet S, Carmona L, Joven BE, Huq M, Proudman S, Nikpour M; Canadian Scleroderma Research Group; Australian Scleroderma Interest Group. Hao Y, et al. Arthritis Rheumatol. 2017 May;69(5):1067-1077. doi: 10.1002/art.40027. Epub 2017 Apr 6. Arthritis Rheumatol. 2017. PMID: 28029745
Assessment of reproductive history in systemic sclerosis.
Bernatsky S, Hudson M, Pope J, Vinet E, Markland J, Robinson D, Jones N, Docherty P, Abu-Hakima M, Leclercq S, Dunne J, Smith D, Mathieu JP, Khalidi N, Sutton E, Baron M; Canadian Scleroderma Research Group. Bernatsky S, et al. Among authors: abu hakima m. Arthritis Rheum. 2008 Nov 15;59(11):1661-4. doi: 10.1002/art.24198. Arthritis Rheum. 2008. PMID: 18975360 Free article.
35 results